Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia
Executive Summary
Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is maintaining focus on same molecule in hyperphosphatemia.
You may also be interested in...
Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia
The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.
Phase III Win In Kidney Disease For Ardelyx's Tenapanor
Ahead of a 12 September PDUFA date for irritable bowel syndrome, the US firm's tenapanor has also succeeded in a second trial as a treatment for hyperphosphatemia.
Ardelyx Outlines Next Phase III Steps For Tenapanor, Ditches RDX7675
New Phase III study of tenapanor in hyperphosphatemia will include an active control arm for safety monitoring, per US FDA guidance, slightly lengthening timeline.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports